$Moderna (MRNA.US)$ In the short term, Moderna can't be bott...

In the short term, Moderna can't be bottom-fishing? There are several points of logic:

1) There will be a glut of COVID-19 vaccines in countries with purchasing power in Q4.

2) Merck's oral drug Lagevrio was approved in the UK on November 4 and is expected to be marketed by the US FDA in December.

3) There will be no significant new product launch for Moderna in the near future. The second product is likely to be a mutated mRNA COVID-19 vaccine.